Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Non-Current Liabilities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $981.8 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 12.75% to $981.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $981.8 million through Dec 2025, up 12.75% year-over-year, with the annual reading at $981.8 million for FY2025, 12.75% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $981.8 million at ImmunityBio, down from $1.0 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $1.1 billion in Q3 2024, with the low at $393.9 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $827.3 million, with a median of $858.0 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities surged 110.37% in 2021, then dropped 18.02% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $712.8 million in 2021, then increased by 13.87% to $811.7 million in 2022, then rose by 19.7% to $971.6 million in 2023, then dropped by 10.38% to $870.7 million in 2024, then increased by 12.75% to $981.8 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $981.8 million, $1.0 billion, and $971.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.